Clinical Trial Update: 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of 9MW2821 in combination with toripalimab for perioperative urothelial carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• 9MW2821
• Toripalimab (Toripalimab)

Snippet

Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. | Conditions: Urothelial Carcinoma | Phase 2 | Status: RECRUITING